Codapedia is now a division of Find-A-Code

Which Drugs Require Intensive Monitoring for Toxicity?

March 22nd, 2013 - Seth Canterbury, CPC, ACS-E/M
 
Question:
When coding E/M services, what drugs qualify as those requiring “intensive monitoring for toxicity” on the MDM Risk table?
 
Answer:
Therapeutic drug monitoring is required for a variety of reasons, one of which is a drug’s high potential for toxicity.
 
Intensive monitoring for toxicity is normally associated with drugs having what’s called a “narrow therapeutic range” or “narrow therapeutic index” (NTI). This means that there is a very small range between the minimum concentration of the drug needed to produce the desired therapeutic effect and the maximum concentration beyond which toxicity or death can result. The concentrations of these drugs must be intensively monitored to ensure that they are in this “sweet spot.”
 
There is no official US Food and Drug Administration (FDA) or government agency list of narrow therapeutic index (NTI) drugs. However, the Board of Pharmacy of some states maintain a list of what they consider to be NTI drugs, a list used to enforce policies which restrict pharmacists from substituting generic equivalents for these drugs without specific consent from the practitioner and/or patient.
 
Also, some payers publish lists of drugs they deem to be NTI drugs, such as Wellmark BC/BS as seen at this link: www.wellmark.com/Products/pharmacy/nti.aspx
 
As stated on Wellmark’s site:
Some drugs are identified as having a narrow therapeutic index (NTI) by the Food & Drug Administration (FDA). With NTI drugs, small changes in the dosage could cause toxic results.
Patients taking NTI drugs require constant monitoring so that the level of medication can be adjusted to assure uniform and safe results. Members will not be required to pay the difference in cost between brand and generic for drugs that are classified as NTI medications.
NTI drugs are identified in the Wellmark Drug List.
For coders, I recommend using an NTI drug list from a state pharmacy board or specific payer if possible, as a starting point for determining which drugs fall into the “drugs that require intensive monitoring for toxicity” category, and add any other drugs that physicians inform you also need this intensive monitoring along with the reason these physicians feel this drug qualifies for this status.

Latest articles:  (any category)

Counting HIPAA Violations
July 20th, 2017 - Wyn Staheli
Information from the Omnibus Rule regarding how HIPAA violations are counted/calculated.
Know how you can leverage your practice performance with 6 revenue cycle metrics
December 20th, 2016 - Ango Mark
Are you one of those busy physicians who pay just a cursory glance at monthly collections? Then you should be prepared to lose revenue every single day like this obgyn practice in southeast Georgia. It is essential for medical practices to track financial performance metrics, as every dollar that...
Looking for a Transcription Comapny? 14 Factors to be considered.
November 21st, 2016 - John Lewis
Apparently choosing a transcription service can just be as simple as Googling for one and opting for the lowest from a list of pricing packages. But is anything that simple? Wait… Is your transcription company specialized in your field? How else can they be accurate when it comes ...
MACRA facts that every clinician should know [Infographic]
November 11th, 2016 - Adam Smith
MACRA is here and the new program is going to sunset several (un) popular programs such as Meaningful Use and the Value Based Payment Modifier model. Everybody who is anybody is busy discussing about MACRA and its ramifications. But as with any big updates the myths are jostling for space with the...
MEDICARE- G0101 & Q0091
October 18th, 2016 - Sreej7
Covered Services Medicare covers the following screening exams along with a Well Woman Exam: 1. G0101 (Cervical or Vaginal Cancer Screening; Pelvic and Clinic Breast Examination): a. G0101 is reimbursed by Medicare every two years, unless the patient is considered high risk, and then it is...
Are harder times coming for CFOs? A data driven answer [Infographic]
October 13th, 2016 - Ango Mark
“We really do believe much harder times are coming from a reimbursement standpoint”, Daniel Morissette, Stanford Health Care CFO. With value based model, the most unpredictable payment reform, in their list of financial challenges, CFOs point out their threats and decision making...
You can charge for Advanced Care Planning (ACP)
October 5th, 2016 - Chris Woolstenhulme, CPC, CMRS
Did you know you could be charging for Advanced Care Planning (ACP). Effective January 1, 2016, payment for the service described by CPT code 99497 (Advance care planning including the explanation and discussion of advance directives such as standard forms (with completion of such forms, when performed), by the physician or ...

About Codapedia & Find-A-Code Contact Us Terms of Use Privacy Policy Advertise with Us

Codapedia™/Find-A-Code™ - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain) - Fax (801) 770-4428

Copyright © 2009-2017 Find A Code, LLC - CPT® copyright American Medical Association